# Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

> **NCT07210125** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Kelley-Ross & Associates, Inc.** · enrollment: 75 (estimated)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Lenacapavir long-acting
- **OTHER:** Standard of Care (SOC)

## Key facts

- **NCT ID:** NCT07210125
- **Lead sponsor:** Kelley-Ross & Associates, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-16
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07210125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07210125, "Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07210125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*